HER2 gene amplification in patients with breast cancer with equivocal IHC results

• Published in: Journal of clinical pathology Vol. 64; no. 12; pp. 1069 - 1072
• Main Authors: Meijer, Sybren L, Wesseling, Jelle, Smit, Vincent T, Nederlof, Petra M, Hooijer, Gerrit K J, Ruijter, Henrique, Arends, Jan Willem, Kliffen, Mike, van Gorp, Joost M, Sterk, Lotus, van de Vijver, Marc J
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and Association of Clinical Pathologists 01.12.2011; BMJ Publishing Group; BMJ Publishing Group LTD
• Subjects: Biological and medical sciences; Breast cancer; Breast Neoplasms - genetics; breast pathology; cancer genetics; cancer research; Cancer therapies; cerb 2; Chemotherapy; Chromosomes; CISH; colorectal cancer; comparative genomic hybridisation; diagnostics; equivocal test result; familial cancers; Female; gall bladder; Gene amplification; Gene Amplification - genetics; Genes, erbB-2 - genetics; GI neoplasms; gynaecological pathology; Gynecology. Andrology. Obstetrics; HER2; Humans; image analysis; immunocytochemistry; Immunohistochemistry; in situ hybridisation; In Situ Hybridization - methods; Investigative techniques, diagnostic techniques (general aspects); Kinases; Laboratories; Mammary gland diseases; Medical prognosis; Medical sciences; molecular oncology; molecular pathology; oncology; p53; pancreas; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Protein expression; Proteins; Tumors; California; Human; Mammary gland diseases; Gene amplification; Anatomic pathology; Breast disease; erbB2 Gene; Breast cancer; Malignant tumor; Cancer

AimsEquivocal human epidermal growth factor receptor 2 protein (HER2) (2+) immunohistochemistry (IHC) is subject to significant interobserver variation and poses a challenge in obtaining a definitive positive or negative test result. This equivocal test result group accounts for approximately 15% of...